The PREcoopERA study (GBG112 / EU CT number: 2022-503013-32) is a window-of-opportunity study of giredestrant +/- triptorelin compared to anastrozole + triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer, sponsored by the ETOP IBCSG Partners Foundation.
☝ The global inclusion period of the study was set from January 2024 to July 2025.
We were able to enrol the first patient on 28 February 2024.
➡ With 18 out of 35 randomised and 22 out of 35 screened patients, we have already reached 50% of our target in just under 6 months!
➡In total, 64 of the planned 220 patients have already been randomised.
🎗 Let's keep up the good work!
